Feb 02 2012 |
more articles from
|
Notification of Major Interests in Shares
LONDON, 2 February 2012 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (DIFX: HIK), the fast growing multinational pharmaceuticals group, announces as follows:
| 1 | Identity of the issuer or the underlying issuer of existing shares to which the voting rights are attached |
|
|
|
|
|
| An acquisition or disposal of voting rights | Yes | |
| An acquisition or disposal of financial instruments which may result in the acquisition of shares already issues to which voting rights are attached | No | |
| An event changing the breakdown of voting rights | No | |
| Other (please specify): Compliance with the Transparency Directive | No |
| 3 | Full name of the person subject to the notification obligation | Artio Global Management LLC |
| 4 | Full name of shareholders | N/A |
| 5 | Date of the Transaction (and date on which the threshold crossed is reached differently) | 31 January 2012 |
| 6 | Date on which the issuer notified | 2 February 2012 |
| 7 | Threshold that is crossed | 4% |
| 8 | Notified details (ABC) |
| A. Voting rights attached to shares | ||||||||
| Class type of shares (if possible using the ISIN code) | Situation previous to the triggering transaction | Resulting situation after the triggering transaction | ||||||
| Number of shares | Number of voting rights | Number of shares | Number of voting rights | % of voting rights | ||||
| Direct | Indirect | Direct | Indirect | Direct | Indirect | |||
| Ordinary Shares (0.10 GBP) GB00B0LCW083 | 8,289,298 | 8,289,298 | 6,986,392 | 0 | 0 | 6,986,392 | 0% | 3.57% |
| B. Qualifying Financial instruments | ||||
| Resulting situation after the triggering transaction | ||||
| Type of financial instrument | Expiration Date | Exercise/Conversion Period/Date | Number of voting rights that may be acquired if the instrument if exercised/converted | % of voting rights |
| - | - | - | - | - |
| C: Financial Instruments with similar economic effect to Qualifying Financial Instruments | ||||||
| Resulting situation after the triggering transaction | ||||||
| Type of financial instrument | Exercise Price | Expiration Date | Exercise/Conversion Period/Date | Number of voting rights instrument refers to | % of voting rights | |
| Nominal | Delta | |||||
| - | - | - | - | - | - | - |
| Total A+B+C | |
| Number of Voting rights | % of voting rights |
| 6,986,392 | 3.57% |
| 9 | Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable | |
|
|
|
| Proxy Voting | ||
| 10 | Name of the proxy holder | Artio Global Management LLC |
| 11 | Number of voting rights proxy holder will cease to hold | N/A |
| 12 | Date on which proxy holder will cease to hold voting rights | N/A |
| 13 | Additional Information |
|
| 14 | Contact name: | Donald Delano Chief Compliance Officer |
| 15 | Contact telephone number: | +1 (212) 297 3628 |
- Ends -
About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed pharmaceutical products. Hikma 's operations are conducted through three businesses: "Branded", "Injectables" and "Generics". Hikma 's operations are based principally in the Middle East and North Africa ("MENA") region, where it is a market leader and sells across 17 countries, the United States and Europe. In 2010, the Group achieved revenues of $731 million (2009 $637 million) and profit attributable to shareholders of $99 million (2009 $78 million).
© Press Release 2012
Zawya Comment Policy
-
Zawya encourages you to add a comment to this discussion. You agree that when you add content to this discussion your comments will not:
1.1 Contain any material which is libelous or defamatory of any person, is obscene, offensive, hateful or inflammatory or causes damage to the reputation of any person or organisation.
1.2 Promote sexually explicit material, violence, discrimination based on race, sex, religion, nationality, disability, sexual orientation or age or any illegal activity.
1.3 Be made in breach of any legal duty owed to a third party, such as a contractual duty or a duty of confidence.
1.4 Be threatening, abuse or invade another's privacy, or cause annoyance, inconvenience or needless anxiety.
1.5 Be used to impersonate any person, to misrepresent your identity or affiliation with any person, or be likely to deceive any person.
1.6 Give the impression that they represent Zawya.
1.7 Advocate, promote or assist any unlawful act such as (by way of example only) copyright infringement or computer misuse. - The content posted on www.zawya.com is created by members of the public. The views expressed are theirs and unless specifically stated are not those of Zawya. Zawya reserves the right to review all comments prior to posting and edit or delete any contribution, but Zawya is not responsible for and can not be held liable for any content posted by members of the public on www.zawya.com.
- Zawya is not responsible for the availability or content of any third party sites that are accessible through www.zawya.com. Any links to third party websites from www.zawya.com do not amount to any endorsement of that site by Zawya and any use of that site by you is at your own risk.
- By submitting your comment, you hereby give Zawya the right, but not the obligation, to post, air, edit, exhibit, telecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comments worldwide, in perpetuity.
Copyright © 2012 Zawya Ltd. All rights reserved. |
provided by www.zawya.com |
Post Your Comment